LAUSR

1. Mills JC, Harman JS, Cook RL, Marlow NM, Harle CA, Duncan RP, et al. Comparative effectiveness of dual vs single-action antidepressants on HIV clinical outcomes in HIV-infected people with depression. AIDS 2017doi: 10.1097/ QAD.0000000000001618. [Epub ahead of print]. 2. Ostad Haji E, Hiemke C, Pfuhlmann B. Therapeutic drug monitoring for antidepressant drug treatment. Curr Pharm Des 2012; 18:5818–5827. 3. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011; 44:195–235. 4. Baldelli S, Fucile S, Cattaneo D, Clementi E. Development of a LC-MS/MS method for therapeutic drug monitoring of antidepressants and antipsychotics in human plasma. Ther Drug Monit 2011; 33:528. 5. Hill L, Lee KC. Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics. Ann Pharmacother 2013; 47:75–89. 6. Siccardi M, Marzolini C, Seden K, Almond L, Kirov A, et al. Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. Clin Pharmacokinet 2013; 52:583–592. 7. Gallego L, Barreiro P, López-Ibor JJ. Psychopharmacological treatments in HIV patients under antiretroviral therapy. AIDS Rev 2012; 14:101–111.